There are thousands of genes in the human genome that all have different purposes. At least 3,000 of these genes are known to express proteins that can be altered by different medications, however, the FDA has only approved drugs that target around 10 percent of these genes. That means that there are still thousands of genes that have not been thoroughly studied that, with the help of the right medication, could be targeted to help improve human health. The National Institutes of Health Common Fund has awarded 8 U.S. institutions $5.8 million for a new collaborative three-year program called Illuminating the Druggable Genome (IDG) that will study different genes and their potential to be modified by different medicines.
Read More
0 Comments Click here to read/write comments
Tags: CA, Mount Sinai School of Medicine, University of California San Francisco, Texas Medical Center, New York, Southwest, 2015, MSSM, tmc, San Francisco, SFVS, BioResearch Product Faire Event, Houston, NY, TX, UC San Francisco, Biotechnology Vendor Showcase Event, North East